Paid Clinical Trials for Hormone-receptor-positive Breast Cancer

Login to your account

Reset Password

Please Enter Username or Email

Create a free account

I'm a Participant
I'm an Organization

Showing all 5 results

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

by CTG

in Metastatic Breast Cancer, HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer

Other

Florida

Deadline:

06/15/2031

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

by CTG

in Hormone Receptor Positive Breast Carcinoma, Triple Negative Breast Cancer, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma

Other

California

Deadline:

03/31/2029

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

by CTG

in Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone-receptor-positive Breast Cancer, Advanced Solid Tumor, Advanced Breast Cancer

Other

Colorado

Deadline:

06/01/2028

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

by CTG

in Hormone-receptor-positive Breast Cancer, Advanced Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer, Metastatic Breast Cancer, Breast Cancer

Other

California

Deadline:

12/01/2026

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

by CTG

in Small Cell Lung Cancer, Breast Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer

Other

Florida

Deadline:

02/28/2028